Table of Contents
Executive Summary — 7
SWOT
Analysis — 8
United Arab Emirates Pharmaceuticals And
Healthcare Industry SWOT — 8
United Arab Emirates
Political SWOT — 9
United Arab Emirates Economic
SWOT — 10
United Arab Emirates Business Environment
SWOT — 11
Pharmaceutical Business Environment
Ratings — 12
Table: Middle East And Africa Pharmaceutical
Business Environment Ratings for Q309 — 12
Limits To
Potential Returns — 13
Risks To Realisation Of
Returns — 13
UAE - Market Summary — 15
Regulatory Environment — 17
Recent Regulatory
Developments — 17
Pharmaceutical
Advertising — 20
Intellectual Property
Regime — 20
Counterfeit Medicines — 21
Pricing And Reimbursement Regime — 22
Recent Pricing And
Reimbursement Developments — 23
Regional
Harmonisation — 24
Free Trade
Agreements — 26
Industry Trends and
Developments — 27
Epidemiology — 27
Healthcare Sector — 30
Healthcare Sector
Reforms — 31
Recent Healthcare Sector
Developments — 31
Hospital Sector
Developments — 33
Health
Insurance — 34
Recent Health Insurance Industry
Developments — 36
Health Tourism — 36
Domestic Pharmaceutical Sector — 37
Foreign
Companies — 38
Company
Developments — 40
harmaceutical Distribution and
Retail — 41
Recent Developments in Pharmaceutical
Distribution and Retail — 43
Research and
Development — 44
DuBiotech — 44
Medical Devices — 46
Recent Developments In The Medical
Devices Market — 47
Industry Forecast
Scenario — 48
Overall Market
Forecast — 48
Table: UAE - Drug Expenditure Indicators,
Historical Data and Forecasts — 49
Key Growth Factors
– Industry — 50
Table: UAE - Health Expenditure
Indicators, Historical Data and Forecasts — 51
Macroeconomic Scenario — 52
Table: United Arab Emirates -
Economic Activity, 2005-2013 — 54
Prescription Drug Market
Forecasts — 55
Table: UAE - Prescription Market
Indicators, Historical Data and Forecasts (AEDmn unless otherwise
stated) — 56
Patented Drug Market
Forecasts — 57
Patented Drug Market
Forecasts — 57
Table: UAE - Patented Drug Market
Indicators, Historical Data and Forecasts — 57
Generic
Drug Market Forecast — 58
Table: Generic Drug Market
Forecast, 2003-2013 — 59
OTC Drug Market
Forecast — 60
Table: UAE - OTC Drug Market Indicators,
Historical Data and Forecasts (AEDmn unless otherwise
stated) — 61
Pharmaceutical Trade
Forecast — 62
Pharmaceutical Trade
Forecast — 62
Table: UAE - Pharmaceutical Trade
Indicators, Historical Data and Forecasts (US$mn) — 64
Medical Devices — 65
Table: UAE - Medical Device Market
Indicators, Historical Data and Forecasts — 65
Other
Healthcare Forecasts — 66
Table: UAE - Other Healthcare
Indicators, Historical Data and Forecasts — 67
Key Risks
To BMI’s Forecast Scenario — 68
Competitive
Landscape — 69
Company Profiles — 70
Leading Foreign Companies — 70
GlaxoSmithKline — 70
Pfizer — 72
Novartis — 74
Johnson & Johnson
(J&J) — 77
Sanofi-Aventis — 79
Abbott
Laboratories — 81
Merck & Co — 83
Indigenous Manufacturers — 85
Gulf Pharmaceutical
Industries (Julphar) — 85
Globalpharma — 89
Modern Pharmaceutical Company
(MPC) — 91
NeoPharma — 92
Country
Snapshot: UAE Demographic Data — 94
Section 1:
Population — 94
Table: Demographic Indicators,
2005-2030 — 94
Table: Rural/Urban Breakdown,
2005-2030 — 95
Section 2: Education And
Healthcare — 95
Table: Education,
2002-2005 — 95
Table: Vital Statistics,
2005-2030 — 95
Section 3: Labour Market And Spending
Power — 96
Table: Employment Indicators,
2000-2004 — 96
Table: Consumer Expenditure, 2000-2012
(US$) — 96
BMI Forecast Modelling — 97
How We Generate Our Pharmaceutical Industry Forecasts — 97
Pharmaceutical Business Environment Ratings
Methodology — 98
Ratings Overview — 98
Table: Pharmaceutical Business Environment Indicators — 99
Weighting — 100
Table: Weighting Of
Components — 100
Sources — 100
| 
View Cart
